Publications

Slide1.JPG
Slide2.JPG
 

Koschmann C, Marini B, Benitez Colon L, Wu Y, Kumar C, Lonigro R, Vats P,  Cao X, Frank K,  Prensner J, Zurieck A, Anderson B, Zamler D, Camelo-Piragua S, Venneti S, Mc Keever P, McFadden K, Lieberman A, Shao L, Pritula L, Gupta A, Everett J, Leonard M, Maher C, Garton H, Muraszko K, Lowenstein PR, Castro MG, Robertson PR, Robinson D, Chinnaiyan A, and Mody R (2018).  Clinically integrated sequencing significantly alters therapy in children and young adults with high-risk glial brain tumors.  JCO Precision Oncology.   2018 May 4.  10.1200/PO.17.00133

Yadav V, Altshuler D, Kadiyala P, Zamler D, Comba A, Appelman H, Dunn P, Koschmann C, Castro MG, Löwenstein PR (2018).  Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab. Neuro Oncology.  2018 Apr 12. doi: 10.1093/neuonc/noy055. [Epub ahead of print].

Pratt D, Natarajan S, Banda A, Giannini C, Vats P, Koschmann C, Mody R, Chinnaiyan A, Venneti S. Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas (2018). Acta Neuropathologica. 2018 Jan 4. doi: 10.1007/s00401-018-1805-3.

Linzey J, Bernard M, Pasternak A, Smith C, Miklja Z, Zhao L, Kumar-Sinha C, Paul A, Harris N, Robertson P, Hoffman L, Chinnaiyan, Mody R and Koschmann C (2017).  Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology.  J Neuro-Oncology.  doi.org/10.1007/s11060-017-2708-1

Linzey J, Marini B, McFadden K, Lorenzana A, Mody R, Robertson P and Koschmann C (2017). Identification and targeting of a novel FGFR fusion in a pediatric thalamic “central oligodendroglioma.” npj Precision Oncology.  1, Article number: 29 (2017) 

Marini B, Benitez L, Zureick A, Salloum R, Gauthier A, Brown J, Wu Y, Robinson D, Kumar C, Lonigro R, Vats P, Cao X, Kasaian K, Anderson B, Mullan B, Chandler B, Linzey J, Camelo-Piragua S, Venneti S; Mc Keever P, McFadden K, Lieberman A, Brown N, Shao L, Leonard M; Junck L, McKean E, Maher C, Garton H, Muraszko K, Hervey-Jumper S, Mulcahy-Levy J, Greem A, Hoffman L, Dorris K, Vitanza N, Wang J, Schwartz J, Lulla R, Pillay Smiley N, Bornhorst M, Haas-Kogan D, Robertson P, Chinnaiyan A, Mody R and Koschmann C (2017). Blood brain barrier-adapted precision medicine therapy for pediatric brain tumors. Translational Research2017 Oct;188:27.e1-27.e14.

Shao L, Miller S, Koschmann C, Camelo-Piragua S (2017). Clinical Application of Whole Genome Array Improves the Diagnosis of Pediatric Brain Tumors.  International Journal of Surgical Pathology.  2017 Aug 1:1066896917727349.

Rogawski S, Vitanza N, Gauthier A, Ramaswamy V, and Koschmann C (2017). Integrating RNA sequencing into neuro-oncology practice.  Translational Research.  2017 Jul 8. pii: S1931-5244(17)30229-3.

Tran D, Camelo-Piragua S, Gupta A, Gowans K, Robertson P, Mody R, and Koschmann C (2017). Loss of CDKN1C in a Recurrent Atypical Teratoid/Rhabdoid Tumor.  Journal of Pediatric Hematology. 2017 Jul 20. doi: 10.1097.

Chandran M, Candolfi M, Mineharu Y, Yadav V, Koschmann C, Shah D, Lowenstein PR and Castro MG (2017).  Single vs. Combination Immunotherapies for Glioblastoma. Expert Opinion Biologic Therapy. 2017 May;17(5):543-554.

Koschmann C, Nunez FJ, Mendez F, Brosnan-Cashman J, Meeker A, Lowenstein PR and Castro MG (2017).  Mutated chromatin regulatory factors as tumor drivers in cancerCancer Research. 2017 Jan 15;77(2):227-233.

Bruzek A, Zureick, A, Mc Keever P, Garton, H, Robertson, P., Mody R, and Koschmann C (2016). Molecular characterization reveals NF1 loss and FGFR1 activating mutation in pediatric spinal oligodendroglioma.  Pediatric Blood and Cancer.  2017 Jun;64(6).

Upadhyaya SA, Koschmann C, Muraszko K, Venneti S, Garton HJ, Hamstra DA, Maher CO, Betz BL, Brown NA, Wahl D, Weigelin HC, DuRoss KE, Leonard AS, Robertson PL (2016).  Brainstem Low-Grade Gliomas in Children-Excellent Outcomes with Multimodality Therapy.  J Child Neurol. 2017 Feb;32(2):194-203.

Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, Castro MG (2016). Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget. 2016 Oct 4;7(40):65696-65706.

Kamran N, Calinescu C, Candolfi M, Mineharu Y, Assad A, Koschmann C, Nunez FJ, Lowenstein PR and Castro MG (2016).  Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther.  2016 Oct;16(10):1245-64.

Koschmann C, Lowenstein PR and Castro MC (2016).  ATRX Mutations and Glioblastoma: Impaired DNA Damage Repair, Alternative Lengthening of Telomeres, and Genetic Instability.  Molecular and Cellular Oncology.  2016 Apr 27;3(3):e1167158.

Koschmann C, Bloom K, Upadhyaya, S, Geyer, JR, Leary, SES (2016).  Survival after relapse of medulloblastoma.  Journal of Pediatric Hematology-Oncology.  May 1;38(4):269-73.

Koschmann C, Calinescu AA, Nunez FJ, Mckay A, Fazal Salom J, Thomas D, Mulpuri L, Kamran N, Mendez F, Dzaman M, Krasinkiewicz J, Doherty R, Lemons R, Li Y, Brosnan-Cashman J, Roh S, Zhao L, Ferguson D, Appelman H, Gorbunova V, Meeker A, Jones C, Lowenstein PR and Castro MC (2016).  ATRX loss promotes tumor growth and impairs non-homologous end joining DNA repair in glioma.  Science Translational Medicine. Mar 2;8(328):328ra28

Calinescu AA, Nunez FJ, Koschmann C, Kolb B, Lowenstein PR, and Castro MC (2015).  Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma.  JoVE2015 Feb 22;(96).

Castro MG, Candolfi M, Wilson TJ, Calinescu A, Paran C, Kamran N, Koschmann C, Moreno-Ayala MA, Assi H, Lowenstein PR (2014). Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther. Sep;14(9):1241-57.

Baker G, Yadav V, Motsch S, Koschmann C, Calinescu A, Mineharu Y, Camelo-Piragua S, Orringer D, Bannykh S, Nichols W, deCarvalho A, Mikkelsen T, Castro M, Lowenstein P (2014).  Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.  Neoplasia. Jul;16(7):543-61.

Lynes J, Wibowo M, Koschmann C, Baker G, Saxena V, Muhammad A, Bondale N, Klein J, Lugo C, Assi H, Lieberman A, Castro M, Lowenstein P (2014).  Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132HNeurotherapeutics. Jul;11(3):623-35.

Koschmann C, Park J, Hawkins D, Bender M, Winter L, Pendergrass C, Luks A. (2012). Pediatric Hematology-Oncology Case-Based Lecture Series. AAMC MedEdPORTAL. Available from: www.mededportal.org/publication/9120

Koschmann C, Thomson B, and Hawkins DS (2010).  No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia.  Arch Pediatr Adolesc Med., 164(3):214-217.